Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer #breastcancer #ASCO2025

Targeting ESR1 mutations early with camizestrant and a CDK4/6 inhibitor may help delay bone disease and improve quality of life, according to Dr. Massimo Cristofanilli during an interview with CURE at the 2025 ASCO Annual Meeting. #breastcancer #oncology

Cristofanilli explains that controlling bone involvement, which often causes pain and reduced quality of life, is a major goal. Early targeting of ESR1 may not only delay progression but also potentially extend survival by halting the mutation’s impact before further damage occurs.

Cristofanilli is the director of Breast Medical Oncology, professor of Medicine, and associate director of Precision Oncology at Weill Cornell Medicine; attending physician at New York-Presbyterian.

View more at http://curetoday.com/

Or visit our socials!

CURE has become the largest consumer magazine in the United States, focusing entirely on cancer. With a total circulation of 285,000, individual subscribers account for over 140,000 of that figure, with the remainder including cancer centers and advocacy groups around the country. CURE’s time-tested approach combines science, humanity and technology to make cancer understandable for patients and their caregivers.